Publicaciones en las que colabora con Begoña Colás Escudero (10)

2023

  1. Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

    International Journal of Molecular Sciences, Vol. 24, Núm. 1

2021

  1. The role of epigenetics in the progression of clear cell renal cell carcinoma and the basis for future epigenetic treatments

    Cancers, Vol. 13, Núm. 9

2020

  1. Epigenetic regulation of gfi1 in endocrine-related cancers: A role regulating tumor growth

    International Journal of Molecular Sciences, Vol. 21, Núm. 13, pp. 1-12

2017

  1. A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer

    APMIS, Vol. 125, Núm. 9, pp. 787-796

2016

  1. A DNA Hypermethylation Profile Independently Predicts Biochemical Recurrence Following Radical Prostatectomy

    Urologia Internationalis, Vol. 97, Núm. 1, pp. 16-25

  2. Survival predictors in patients with prostate adenocarcinoma with hormonal blockade

    Pathology Research and Practice, Vol. 212, Núm. 10, pp. 899-903

2014

  1. Prostate anatomy in motheaten viable (mev) mice with mutations in the protein tyrosine phosphatase SHP-1

    Actas Urologicas Espanolas, Vol. 38, Núm. 7, pp. 438-444

2012

  1. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway

    Carcinogenesis, Vol. 33, Núm. 6, pp. 1169-1177

2004

  1. Fosfotirosina fosfatasa SHP-1, somatostatina y cáncer de próstata

    Actas Urologicas Espanolas, Vol. 28, Núm. 4, pp. 269-285

2002

  1. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin through the modulation of the SH2 domain containing protein tyrosine phosphatase (SHP)-1

    Journal of Clinical Endocrinology and Metabolism, Vol. 87, Núm. 2, pp. 915-926